Lilly’s Zepbound beats Novo’s Wegovy in head-to-head trial #shorts #zepbound #wegovy

Eli Lilly said its weight-loss drug Zepbound outperformed rival Novo Nordisk’s Wegovy in the first head-to-head trial of the two blockbusters. Dr. Daniel Skovronsky, Eli Lilly chief scientific officer, spoke to Bloomberg TV about the results https://trib.al/Y3suGBA